Clinical trials: Intermittent Hypoxia
Intermittent Claudication, Peripheral Vascular Disease
Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication
The purpose of this Phase 2 clinical research study is to examine the safety of an experimental gene transfer agent, Ad2/HIF-1α/VP16, and its ability to stimulate the growth of new blood vessels from existing blood vessels (a…
- Conditions
- Intermittent Claudication, Peripheral Vascular Disease, Atherosclerosis
- Trial name
- WALK (NCT00117650)
- Testing
- Ad2/HIF-1α/VP16
- Where
- 47 sites in United States, Germany and 1 more
- Volunteers
- 289 people
- Sponsor
- Genzyme, a Sanofi Company